Hong Kong Pharmaceutical Market Analysis

1. A sample report on Hong Kong Pharmaceutical Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2023 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the Hong Kong Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Hong Kong Pharmaceutical Market , and offers unmatched value, accuracy, and expert insights

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

4. Table of Content CONTENT PG. NO. 12-24 1. Pharmaceutical Overview 1.1. Overview 1.2. Hong Kong Overview 1.3. Economic Overview: Hong Kong 1.4. Pharmaceutical Market in Hong Kong 1.5. Healthcare Scenario in Hong Kong 1.6. Health Insurance Coverage: Hong Kong 1.7. Budget of the Government for Public Insurance 1.8. Mergers and Acquisitions 25-30 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. Product 2.2.2. Type 2.2.3. Therapeutic category 31-35 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Hong Kong Pharmaceutical Market Driver 1 3.1.2. Hong Kong Pharmaceutical Market Driver 2 3.2. Market Restraints 3.2.1. Hong Kong Pharmaceutical Market Restraint 1 5 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

6. Table of Content CONTENT PG. NO. 3.2.2. Hong Kong Pharmaceutical Market Restraint 2 3.2.3. Hong Kong Pharmaceutical Market Restraint 3 36-42 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Sino Biopharmaceutical limited 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 6 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

7. Table of Content CONTENT PG. NO. 4.2.2. Lee’s Pharmaceutical Holdings limited 4.2.2.2. Overview 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Chong Kun Dang Pharmaceutical 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 7 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

8. Table of Content CONTENT PG. NO. 4.2.4. Hoffmann- La Roche 4.2.4.2. Overview 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Novartis 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 8 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

9. Table of Content CONTENT PG. NO. 4.2.6. GlaxoSmithKline 4.2.6.1. Overview 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Pfizer 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 9 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

10. Table of Content CONTENT PG. NO. 4.2.8. Merck and co. 4.2.8.1. Overview 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Sanofi 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 10 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

11. Table of Content CONTENT PG. NO. 4.2.10. AstraZeneca 4.2.10.2. Overview 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 43-47 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Nutritional Supplements 48-75 6. Methodology & Scope 11 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

12. Hong Kong Pharmaceutical Market 1. Pharmaceutical Market Overview

13. 1.1 Statistics at a Glance: Pharmaceuticals in the world Prevalence of Pharmaceuticals Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Oncology Is one of the largest pharmaceutical segment which accounted for $99.5 Bn sales in 2022 $1.48 Tn Revenue from global pharmaceutical market in 2022 In this section you will get an understanding of the topic, which includes the prevalence of Pharmaceutical, CAGR and revenue , new technology, and other details related to the topic ▪ 41,517 Plus pharmaceutical companies are registered in international directory of pharmaceutical companies 202222 6147 Pharmaceutical products were in active development from phase 1 to regulatory submission in 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ United States Is the largest pharmaceutical market in the world accounting for 47% of the total global sales Biotech Segment is predicted to account for 35 % of spending globally in 2027 Illustrative Illustrative 13 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

14. 1.1 Statistics at a Glance: Pharmaceutical in the World (continued) Europe ~Revenue to reach $XX Bn by 2027 North America ~ Market Size of $XX Bn Asia -$XX Mn Market Hong Kong Market ~$xx Mn Market Africa ~Market Size of $XXBn Illustrative Illustrative 14 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

15. 1.2 Hong Kong Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 7.37 Bn Is the population of Hong Kong, in 2022 $429 Bn Is the Gross Domestic Product (GDP) of Hong Kong in 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 45.3 Is the median age in Hong Kong, in 2022 $25,300 Per capita was the amount of national health expenditures in 2022 Illustrative Illustrative 15 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

16. 1.3 Economic Overview: Hong Kong Population of Hong Kong, (2020-2030) GDP of Hong Kong, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 47.34 Female 52.66 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

17. 1.4 Statistics at a Glance: Pharmaceutical in Hong Kong Prevalence of Pharmaceutical Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Cold and Cough remedies Accounted for the highest revenue in OTC pharmaceuticals on Hong Kong in 2022 1218 Clinical trials were conducted in Hong Kong in 2022 for development of new pharmaceuticals In this section you will get an understanding of the topic, which includes the prevalence of Pharmaceutical in Hong Kong, new technology, and other details related to the topic in Hong Kong ▪ 54.7% Market share in Hong Kong pharmaceutical market was held by proprietary medicines in 2019 $86.4 Mn Worth pharmaceutical products were exported from Hong Kong to Macau in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 32% Revenue in OTC pharmaceuticals market in Hong Kong was generated through online sales in 2022 $2.3 Bn Hong Kong pharmaceutical market size in 2021 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 17 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

18. 1.5 Healthcare Scenario in Hong Kong Hong Kong Pharmaceutical Market: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 18 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

19. 1.5 Healthcare Scenario in Hong Kong: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 19 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

20. 1.6 Health Insurance Coverage: Hong Kong % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 20 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

21. 1.7 Budget of Hong Kong Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 In Billions Of Dollars Public Insarance 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% As % Of GDP National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 21 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

22. 1.8 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 22 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

23. 1.8 Mergers and Acquisitions (continued) Latest Deals In Hong Kong Amount / Duration Company Name Type Year Key Pointers Aim of the deal is advance life science innovation in Hong Kong and the Greater Bay Area (GBA) The collaboration will focus on three key areas Policy shaping, startup co incubation and health data sharing in ethical manner The long-term goal is to turn the GBA into a national leader in life science and healthcare innovation, and setting an example the rest of the country might follow in technology application and registration. ▪ ▪ Collaboration $Xx Mn 2023 ▪ Illustrative Illustrative 23 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

24. Hong Kong Pharmaceutical Market 2. Market Size and Forecasting

25. 2.1 Market Size and Forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Hong Kong Pharmaceutical Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Pharmaceutical market in Hong Kong, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 Major Markets Patient (Mn) In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Hong Kong Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ % of Hong Kong Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Hong Kong Market Size (Bn $) 61 74 84 87 91 95 99 106 Illustrative Illustrative 25 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

26. 2.2 Snapshot of Pharmaceutical Market Segmentation By Product By Therapeutic Category By Type Branded Oncology Prescription Cardiovascular Diseases Generic OTC Anti-infectives Central Nervous System Disorders Metabolic Disorders Gastrointestinal Disorders Respiratory Diseases Others In this section you will get an understanding of the segmentations which will cover the Hong Kong Pharmaceutical Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 26 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

27. 2.2.1 Market Segmentation: By Product Branded products are a significant component of the overall Pharmaceutical market in Hong Kong ▪ Hong Kong Pharmaceutical Market Share, By Product (2022) It has the maximum market share in Hong Kong Pharmaceutical market with approximately xx% ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Generic In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Branded 27 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

28. 2.2.2 Market Segmentation: By Type Prescription Products is a significant component of the overall Pharmaceutical market in Hong Kong ▪ Hong Kong Pharmaceutical Market Share, By Type (2022) It has the maximum market share in Hong Kong Pharmaceutical market with approximately xx% ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ OTC In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Prescription Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 28 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

29. 2.2.3 Market Segmentation: By End User Cardiovascular diseases, central nervous system disorders and oncology have the maximum market share in Hong Kong Pharmaceutical market with approximately xx% ▪ Hong Kong Pharmaceutical Market Share, By End User (2022) Respiratory diseases Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Cardiovascular diseases Gastrointestinal disorders In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Metabolic disorders Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Central nervous system diseases Anti-infectives Oncology 29 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

30. Hong Kong Pharmaceutical Market 3. Market Dynamics

31. 3.1 Market growth drivers (continued) 3.1.1 Increase in export of pharmaceutical products from Hong Kong to bordering countries like China and Macau acts as a market growth driver for Hong Kong pharmaceutical market Increase in export of pharmaceutical products to other countries like China and Macau acts as a market growth driver for Hong Kong pharmaceutical market ▪ Increase in Export of Pharmaceutical Products $86.4 Mn pharmaceutical products were exported from Hong Kong to Macau in 2021 ▪ Development of Guangdong-Hong Kong-Macao Greater Bay Area (GBA) where ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 31 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

32. 3.1 Market growth drivers (continued) 3.1.2 Growing geriatric population in Hong Kong with over 1.48 Mn population above 65 years in 2022 which is projected to reach above 1.6 Mn in 2050 Geriatric population make up a significant component of the total population of Hong Kong which is also projected to increase significantly in the coming years ▪ Increase in Geriatric Population in Hong Kong Geriatric individuals suffer from chronic diseases which acts as market growth driver for Pharmaceutical market in Hong Kong ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 32 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

33. 3.2 Market restraints 3.2.1 Prevalence of Traditional Chinese Medicines in Hong Kong 3.2.2 Regulatory challenges in approval of new drugs 3.2.3 High costs of research and development of pharmaceutical products in Hong Kong Traditional Chinese medicines are prevalent and highly accepted in Hong Kong Drugs in Hong Kong are divided into two main categories of Chinese medicines and western medicines This factor thus acts as a market growth restraint for acceptance of newly developed pharmaceuticals in Hong Kong Presence of strict regulatory guidelines in registration and approval of pharmaceuticals acts as a market growth restraint Drug office of Department of Health, government of Hong Kong is responsible for regulating the safety and efficacy of pharmaceuticals in Hong Kong High costs of Research and development of development of pharmaceutical products are involved in Hong Kong Pharmaceutical companies are thus shifting their Research and development plants in China thus acting as a market growth restraint to Hong Kong pharmaceutical market ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 33 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

34. Hong Kong Pharmaceutical Market 4. Competitive Landscape

35. 4.1 Major Market Share Revenue of Major Players in Hong Kong Pharmaceutical Market ($ Mn) Other Some of the top companies in Hong Kong Pharmaceutical Market based on revenue and market share include ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ XX Illustrative Illustrative 35 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

36. 4.2 Key Company Profile 1 Sino Biopharmaceutical Key Notes Lee's Pharmaceutical Holdings Limited 2 Here is the list of top 10 companies which will cover in the final report Each company will have slides for Overview o Key details o Offerings o Name of products o Recent activities/ Press Coverage o Distribution and Vendor Partners o Mergers, Acquisitions and Collaboration o Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Chong Kun Dang Pharmaceutical 3 ▪ 4 Hoffmann-La Roche o 5 Novartis 6 GlaxoSmithKline 7 Pfizer 8 ▪ Merck & Co. 9 Sanofi ▪ 10 AstraZeneca Illustrative Illustrative 36 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

37. 4.2.1 SINO BIOPHARMACEUTICAL LIMITED Solutions offered by Company Founded in: 2000 ▪ Sino Biopharmaceutical limited is currently the second largest pharma company in China in terms of revenue ▪ It has above 25000 employees in 2021 and its 40 innovate drug candidates have potential to launch by 2040 ▪ Sino Biopharmaceutical limited has more than 1400 invention patents and employees above 2700 individuals in R and D team ▪ Sino Biopharmaceutical limited mission is science for a healthier world ➢ Diagnostics HQ: Beijing, China ➢ Pharmaceuticals Type: Private ➢ Research and development Revenue: $3760 Bn ➢ Clinical Trials Website: www.sinobiopharm.com Therapeutic Portfolio Recent Activity / Press Coverage On February 20, Sino Biopharmaceutical announced that Liamprost tablet (brand name: Kelitone ®), a treatment for lumbar spinal stenosis developed by its subsidiary of Beijing Tide, has been approved by the National Medical Products Administration (NMPA) Oncology Surgery Hepatology Analgesic In March 2023, invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, announced that it has successfully completed the acquisition of F-star Therapeutics, Inc. Respiratory Others Illustrative Illustrative 37 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

38. 4.2.1 SINO BIOPHARMACEUTICAL LIMITED Partnerships Ecosystem Illustrative Illustrative 38 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

39. 4.2.1 DOCTOR ANYWHERE Latest Deals - Mergers and Acquisitions Amount / Shares Company Type Year Key Pointers invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) with an advancing pipeline of innovative products, has successfully completed the acquisition of F-star Therapeutics, Inc. (“F-star”) a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy invoX will now be able to develop next generation immunotherapies to treat cancer patients through a leading and differentiated bispecific antibody platform ▪ Acquisition $161 Mn March 2023 ▪ Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of next generation biologics using an expanded genetic code and Sino Biopharmaceutical Limited (1177.HK), a leading Chinese pharmaceutical company with a large number of medical products covering multiple therapeutic areas, announced a joint collaboration to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms. ▪ Collaboration -- January 2020 Illustrative Illustrative 39 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

40. 4.2.1 SINO BIOPHARMACEUTICAL LIMITED Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 40 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

41. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 41 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

42. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 42 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

43. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 43 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

44. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 44 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

45. Hong Kong Pharmaceutical Market 5. Reimbursement Scenario

46. 5.1 Reimbursement Regulation in Hong Kong Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Population The reimbursement scenario in Hong Kong nutritional supplement market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Public Insurance: o Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions o Medicare covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies o However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for cancer treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage ▪ Other Public 1% Other Private 3% Uninsured 9% Medicare 17% Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 46 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

47. 5.1 Reimbursement Regulation in Hong Kong (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as cancer Reimbursement for New Treatments: Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 47 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

48. 5.1 Reimbursement Regulation in Hong Kong (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities  Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 48 A Sample Report on Hong Kong Pharmaceutical Market I Confidential

49. Hong Kong Pharmaceutical Market 6. Methodology & Scope

50. Research Methodology Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources For forecasting, the following parameters are considered: ❑ Market drivers and restraints along with their current and expected impacts ❑ Technological scenario and expected developments ❑ End use industry trends and dynamics ❑ Trends in the consumer behavior ❑ Regulatory scenario and expected developments ❑ Current capacity and expected capacity additions up to 2030 We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time- sensitive, reflecting the most recent value and volume of the market across regions All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs) Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn) ▪ ▪ ▪ ▪ ▪ ▪ ▪